Surgery
Volume 27, Issue 11 , Pages 465-469 , November 2009

The basic science of sepsis

References 

  1. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/EISCM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:521–524
  2. Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin. 2008;24:1–47
  3. Vincent J-L, Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med. 2006;173:256–263
  4. Cohen J. The immunopathogenesis of sepsis. Nature. 2004;420:885–891
  5. Vilcek J, Feldman M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci. 2004;25:201–209
  6. Gogos CA, Drosou E, Basssaris HP, Skoutelis A. J Infect Dis. 2000;181:176–180
  7. Weighardt H, Holzmann B. Role of toll-like receptor responses for sepsis pathogenesis. Immunobiology. 2007;212:715–722
  8. Cavaillon J-M. Pathophysiological role of pro- and anti-inflammatory cytokines in sepsis. Sepsis. 1998;2:127–140
  9. Marshall JC. Sepsis: current status, future prospects. Curr Opin Crit Care. 2004;10:250–264
  10. Ward NS, Casserley B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008;29:617–625
  11. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–150
  12. Aldridge AJ. Role of the neutrophil in septic shock and the adult respiratory distress syndrome. Eur J Surg. 2002;168:204–214
  13. Puneet P, Moochala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2005;288:3–15
  14. Sato T, Shinzawa H, Abe Y, et al. Inhibition of Corynebacterium parvum-primed and lipopolysaccharide-induced hepatic necrosis in rats by selective depletion of neutrophils using monoclonal antibody. J Leukoc Biol. 1993;53:144–150
  15. Treacher DF, Sabbato M, Brown KA, et al. The effects of leucodepletion in patients who develop the systemic inflammatory response syndrome following cardiopulmonary bypass. Perfusion. 2001;16:S67–S74
  16. Brown KA, Brain SD, Pearson JD, et al. Neutrophils in development of multiple organ failure in sepsis. Lancet. 2006;368:157–169
  17. Levi M. The coagulant response in sepsis. Clin Chest Med. 2008;29:627–642
  18. Weiler H, Ruf W. Activated protein C in sepsis: the promise of non-anticoagulant activated protein C. Curr Opin Hematol. 2008;15:487–493
  19. Lin SM, Wang YM, Lin HC, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome and morality in patients with sepsis. Crit Care Med. 2008;36:683–689
  20. Cauwels A. Nitric oxide in shock. Kidney Int. 2007;72:57–65
  21. Fernandes CJ, Akamine N, Knobel E. Myocardial depression in sepsis. Shock. 2008;30:14–17
  22. Singer M, De Santis V, Vitale D, et al. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet. 2004;364:545–548
  23. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709
  24. Tolt LJ, Swystun LL, Pepler L, et al. Protective effects of activated protein C in sepsis. Thromb Haemost. 2008;100:589–592
  25. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21–30

PII: S0263-9319(09)00189-6

doi: 10.1016/j.mpsur.2009.09.001

Surgery
Volume 27, Issue 11 , Pages 465-469 , November 2009

Article Tools

* Image Usage & Resolution